The Life Science Sector (^BTK) Overall Has Outperformed Other Major Market Indices Over 10 Years
As we approach year-end we can look back on a great year for all markets and outperformance for the Life Science sector. Benchmark ETF performance is as follows YTD: FBT up 38.8%, IBB up 15.4%, XBI up 19.5%. We have two portfolios: Diagnostics and Tools, and Biopharmaceuticals. Most of our picks are trading near their highs. Here is a brief summary:
Winners 2009-2010
- Abaxis (ABAX $26.81) up 67.5%
- Alera (ALR $36.06) up 80.3%
- Alexion (ALXN $81.14) up 131.8%
- Ardea Biosci (RDEA $26.65) up 122%
- Biogen(BIIB $66.75) up 37.6%
- Illumina (ILMN $63.75) up 134.4%
- GenProbe (GPRO $58.98) up 31.65%
- Regeneron (REGN $33.36) up 90.6%
- Seattle Genomics (SGEN $15.50) up 63%
- SeraCare (SRLS $4.63) up 68.3%
- Sequenom (SQNM $8.11) up 68.36%
- Targacept (TRGT $27.06) up 1130%
- United Therapeutics (UTHR $63.38) up 89%
Winners-Added in 2010
- CardioVascular Systems (CSII $11.14) up 55.8%
- Exact Scientific (EXAS $6.38) up 13.9%
- Exelixis (EXEL $8.87) up 169%
- NeoGen (NEOG $41.95) up 61.35%
Biggest Losers >One Year (all remain in the portfolio)
Celera (CRA $6.40) down 8.70%, Cephalon (CEPH $63.35) down 17.2%, Gilead (GILD $36.25) down 29%.
We will review the Rayno Portfolios in-depth at the end of January and add/delete picks if needed. However we are rebalancing on a weekly basis pending news and technicals. Both Portfolios will be updated with final prices at Year-End 2010.
12/28/10